Domenic A. Sica
#135,452
Most Influential Person Now
Domenic A. Sica's AcademicInfluence.com Rankings
Download Badge
Chemistry
Why Is Domenic A. Sica Influential?
(Suggest an Edit or Addition)Domenic A. Sica's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. (2008) (1933)
- Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. (2008) (1333)
- K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease (2004) (1050)
- Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. (2011) (560)
- Diabetes and Hypertension in Severe Obesity and Effects of Gastric Bypass-Induced Weight Loss (2003) (506)
- Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. (2003) (461)
- Drug dosing consideration in patients with acute and chronic kidney disease-a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). (2011) (375)
- Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. (2001) (349)
- Chronic Vagus Nerve Stimulation Improves Autonomic Control and Attenuates Systemic Inflammation and Heart Failure Progression in a Canine High-Rate Pacing Model (2009) (336)
- Management of high blood pressure in Blacks: an update of the International Society on Hypertension in Blacks consensus statement. (2010) (330)
- Secondary prevention after coronary artery bypass graft surgery: a scientific statement from the American Heart Association. (2015) (276)
- Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. (1994) (252)
- Elevated intra-abdominal pressure increases plasma renin activity and aldosterone levels. (1997) (211)
- Effect of the sodium glucose co‐transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus (2014) (205)
- Clinical Pharmacokinetics of Losartan (2005) (194)
- Effects of the Angiotensin Receptor Blocker Azilsartan Medoxomil Versus Olmesartan and Valsartan on Ambulatory and Clinic Blood Pressure in Patients With Stages 1 and 2 Hypertension (2011) (188)
- Rationale for Fixed-Dose Combinations in the Treatment of Hypertension (2012) (176)
- Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. (2012) (163)
- Pharmacokinetics and Pharmacodynamics of Mineralocorticoid Blocking Agents and their Effects on Potassium Homeostasis (2005) (160)
- Effect of increased renal venous pressure on renal function. (1999) (153)
- Role of Magnesium in Cardiovascular Diseases (2014) (147)
- Effects of increased renal parenchymal pressure on renal function. (2000) (146)
- International expert consensus statement: Percutaneous transluminal renal denervation for the treatment of resistant hypertension. (2013) (138)
- Cardiovascular Burden Associated with Uremic Toxins in Patients with Chronic Kidney Disease (2013) (137)
- Role of Prescription Omega‐3 Fatty Acids in the Treatment of Hypertriglyceridemia (2007) (134)
- Pharmacokinetics of gabapentin in subjects with various degrees of renal function (1994) (132)
- A comparison of outcomes with angiotensin-converting enzyme inhibitors and diuretics for hypertension in the elderly. (2003) (131)
- The Comparative Effects of Azilsartan Medoxomil and Olmesartan on Ambulatory and Clinic Blood Pressure (2011) (131)
- Curcumin ameliorates renal failure in 5/6 nephrectomized rats: role of inflammation. (2009) (130)
- Angiogenesis inhibitors and hypertension: an emerging issue. (2006) (127)
- Head-to-Head Comparisons of Hydrochlorothiazide With Indapamide and Chlorthalidone: Antihypertensive and Metabolic Effects (2015) (123)
- Assessment and management of hypertension in transplant patients. (2015) (122)
- The relationship among restless legs syndrome (Willis–Ekbom Disease), hypertension, cardiovascular disease, and cerebrovascular disease (2013) (119)
- Motivational versus social cognitive interventions for promoting fruit and vegetable intake and physical activity in African American Adolescents (2002) (112)
- Diuretics for Hypertension: A Review and Update. (2016) (112)
- Comparison of loop diuretics in patients with chronic renal insufficiency. (1987) (112)
- Prescription omega-3 fatty acids for the treatment of hypertriglyceridemia. (2007) (104)
- The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency (1999) (102)
- Comparison of the Novel Angiotensin II Receptor Blocker Azilsartan Medoxomil vs Valsartan by Ambulatory Blood Pressure Monitoring (2011) (102)
- Pathophysiology, Diagnosis, and Treatment of Orthostatic Hypotension and Vasovagal Syncope (2008) (101)
- Therapeutic perspectives in hypertension: novel means for renin–angiotensin–aldosterone system modulation and emerging device-based approaches (2011) (98)
- Lead-induced hypertension: Role of oxidative stress (2004) (92)
- Loop diuretic therapy, thiamine balance, and heart failure. (2007) (88)
- Violence Exposure, Catecholamine Excretion, and Blood Pressure Nondipping Status in African American Male Versus Female Adolescents (2002) (86)
- Comparison of the Steady-State Pharmacokinetics of Fosinopril, Lisinopril and Enalapril in Patients with Chronic Renal Insufficiency (1991) (83)
- Minoxidil: An Underused Vasodilator for Resistant or Severe Hypertension (2004) (79)
- Diuretic use in renal disease (2012) (76)
- Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil. (2012) (75)
- Socioeconomic status and blood pressure reactivity in healthy black adolescents. (2000) (71)
- Effects of potassium on blood pressure in salt-sensitive and salt-resistant black adolescents. (1999) (71)
- Acetazolamide: A Forgotten Diuretic Agent (2011) (69)
- Importance of Potassium in Cardiovascular Disease (2002) (68)
- Hyponatremia and heart failure--pathophysiology and implications. (2005) (68)
- Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. (2002) (64)
- Diuretic Combinations in Refractory Oedema States (1996) (63)
- What are the influences of salt, potassium, the sympathetic nervous system, and the renin-angiotensin system on the circadian variation in blood pressure? (1999) (63)
- Sodium and water retention in heart failure and diuretic therapy: basic mechanisms. (2006) (62)
- Cardiac hypertrophy in neonatal nephrectomized rats: the role of the sympathetic nervous system (2009) (62)
- Metolazone and its role in edema management. (2003) (62)
- Chlorthalidone: has it always been the best thiazide-type diuretic? (2006) (62)
- Pharmacotherapy in congestive heart failure: drug absorption in the management of congestive heart failure: loop diuretics. (2003) (61)
- Rhabdomyolysis and statin therapy: relevance to the elderly. (2002) (61)
- Simple high-performance liquid chromatographic method for determination of losartan and E-3174 metabolite in human plasma, urine and dialysate. (1997) (60)
- Azilsartan Medoxomil Plus Chlorthalidone Reduces Blood Pressure More Effectively Than Olmesartan Plus Hydrochlorothiazide in Stage 2 Systolic Hypertension (2012) (60)
- PPARgamma ligand attenuates PDGF-induced mesangial cell proliferation: role of MAP kinase. (2003) (59)
- Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 6: Hypertension: A Scientific Statement from the American Heart Association and the American College of Cardiology. (2015) (58)
- An HPLC method for determination of inosine and hypoxanthine in human plasma from healthy volunteers and patients presenting with potential acute cardiac ischemia. (2007) (58)
- Ambulatory blood pressure nondipping status in salt-sensitive and salt-resistant black adolescents. (1999) (58)
- Interaction of grapefruit juice and calcium channel blockers. (2006) (56)
- Cardiovascular considerations in using topical, oral, and intravenous drugs for the treatment of glaucoma and ocular hypertension: focus on beta-adrenergic blockade. (2001) (55)
- Bilateral or Unilateral Stimulation for Baroreflex Activation Therapy (2015) (55)
- Detection, evaluation, and treatment of severe and resistant hypertension: proceedings from an American Society of Hypertension Interactive forum held in Bethesda, MD, U.S.A., October 10th 2013. (2014) (55)
- Part 1. Uric acid and losartan (2002) (54)
- Curcumin and enalapril ameliorate renal failure by antagonizing inflammation in 5/6 nephrectomized rats: role of phospholipase and cyclooxygenase. (2012) (51)
- Diuretic combinations in refractory oedema states: pharmacokinetic-pharmacodynamic relationships. (1996) (49)
- Curcumin prevents cardiac remodeling secondary to chronic renal failure through deactivation of hypertrophic signaling in rats. (2010) (49)
- Simple method for determination of hydrochlorothiazide in human urine by high performance liquid chromatography utilizing narrowbore chromatography. (1998) (47)
- Pharmacokinetics of propranolol after single and multiple dosing with sustained release propranolol or propranolol CR (innopran XL) , a new chronotherapeutic formulation. (2003) (46)
- Kinetics of Angiotensin-Converting Enzyme Inhibitors in Renal Failure (1992) (44)
- Preventing increases in early-morning blood pressure, heart rate, and the rate-pressure product with controlled onset extended release verapamil at bedtime versus enalapril, losartan, and placebo on arising. (2002) (44)
- A simple and sensitive HPLC fluorescence method for determination of tadalafil in mouse plasma. (2010) (43)
- Acute Phosphate Nephropathy—An Emerging Issue (2007) (42)
- Fixed-dose combination antihypertensive drugs. Do they have a role in rational therapy? (1994) (42)
- Pharmacokinetics of Ertapenem in Patients With Varying Degrees of Renal Insufficiency and in Patients on Hemodialysis (2006) (41)
- Class effects of angiotensin-converting enzyme inhibitors. (2000) (41)
- Severe Hypophosphatemia in a General Hospital Population (1987) (41)
- Blood Pressure–Lowering Efficacy of the Fixed‐Dose Combination of Azilsartan Medoxomil and Chlorthalidone: A Factorial Study (2012) (40)
- Alpha1‐Adrenergic Blockers: Current Usage Considerations (2005) (40)
- Acute brain death alters left ventricular myocardial gene expression. (1999) (40)
- The influence of gender and emotional versus instrumental support on cardiovascular reactivity in African-American adolescents (1999) (40)
- Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril (2013) (39)
- Renal denervation therapy for hypertension: pathways for moving development forward. (2015) (39)
- Simple HPLC-UV method for determination of iohexol, iothalamate, p-aminohippuric acid and n-acetyl-p-aminohippuric acid in human plasma and urine with ERPF, GFR and ERPF/GFR ratio determination using colorimetric analysis. (2005) (39)
- Dose doubling, relative potency, and dose equivalence of potassium-sparing diuretics affecting blood pressure and serum potassium: systematic review and meta-analyses (2016) (38)
- Type 2 Diabetes: RENAAL and IDNT—The Emergence of New Treatment Options (2002) (38)
- Angiotensin‐Converting Enzyme Inhibitors Side Effects—Physiologic and Non‐Physiologic Considerations (2004) (38)
- The relationship between exposure to violence and blood pressure mechanisms (2004) (37)
- Pharmacokinetics of Eplerenone After Single and Multiple Dosing in Subjects With and Without Renal Impairment (2005) (37)
- Variability in salt sensitivity classifications in black male versus female adolescents. (1996) (35)
- Controlled-release carvedilol in the treatment of essential hypertension. (2006) (34)
- Stroke in Patients With Diabetes and Hypertension (2005) (32)
- Direct Inhibition of Renin as a Cardiovascular Pharmacotherapy: Focus on Aliskiren (2007) (32)
- History and Justification of a National Blood Pressure Measurement Validated Device Listing (2019) (32)
- Vancomycin pharmacokinetics in continuous ambulatory peritoneal dialysis patients with peritonitis. (1986) (31)
- 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and rhabdomyolysis: considerations in the renal failure patient (2002) (31)
- Total volume culture technique for the isolation of microorganisms from continuous ambulatory peritoneal dialysis patients with peritonitis (1985) (31)
- Nutritional supplementation with Chlorella pyrenoidosa for mild to moderate hypertension. (2002) (31)
- Efficacy of a Once‐Daily Formulation of Carvedilol for the Treatment of Hypertension (2006) (31)
- Angioedema in heart failure: occurrence with ACE inhibitors and safety of angiotensin receptor blocker therapy. (2002) (31)
- Rotigotine's effect on PLM-associated blood pressure elevations in restless legs syndrome (2016) (30)
- Mannitol-induced acute renal failure. (1987) (30)
- Fibrate therapy and renal function (2009) (29)
- High-performance liquid chromatographic method for determination of vanillin and vanillic acid in human plasma, red blood cells and urine. (1999) (28)
- Solid-phase extraction and determination of ranitidine in human plasma by a high-performance liquid chromatographic method utilizing midbore chromatography. (1997) (28)
- Rheos: An Implantable Carotid Sinus Stimulation Device for the Nonpharmacologic Treatment of Resistant Hypertension (2011) (28)
- Hyperkalemia, congestive heart failure, and aldosterone receptor antagonism. (2003) (28)
- Diuretic use in stage 5 chronic kidney disease and end-stage renal disease (2003) (27)
- Combination Angiotensin‐Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Therapy: Its Role in Clinical Practice (2003) (27)
- Mineralocorticoid Receptor Antagonists for Treatment of Hypertension and Heart Failure. (2015) (27)
- Calcium Channel Blocker Class Heterogeneity: Select Aspects of Pharmacokinetics and Pharmacodynamics (2005) (27)
- Hyponatremia and heart failure--treatment considerations. (2006) (27)
- Determination of flutamide and hydroxyflutamide in dog plasma by a sensitive high performance liquid chromatography method utilizing mid-bore chromatography. (1994) (26)
- The pharmacokinetics of pravastatin in patients on chronic hemodialysis (1997) (25)
- Triamterene and the kidney. (1989) (25)
- Pharmacokinetics and Blood Pressure Response of Losartan in End-Stage Renal Disease (2000) (25)
- Drug treatment of orthostatic hypotension and vasovagal syncope. (2003) (24)
- Comprar Hypertension Primer 4/e (The Essentials of High Blood Pressure: Basic Science, Population Science, and Clinical Management From the Council on High Blood Pressure Research, American Heart Association) | Henry R. Black, MD | 9780781782050 | Lippincott Williams & Wilkins (2007) (24)
- Pharmacology and clinical efficacy of angiotensin receptor blockers. (2001) (24)
- 9.9 Aliskiren, a Novel Renin Inhibitor, is Well Tolerated and Has Sustained BP-Lowering Effects Alone or in Combination with HCTZ During Long-Term (52 Weeks) Treatment of Hypertension (2007) (24)
- External-standard high-performance liquid chromatographic method for quantitative determination of furosemide in plasma by using solid-phase extraction and on-line elution. (1992) (24)
- Combination Calcium Channel Blocker Therapy in the Treatment of Hypertension (2001) (24)
- Novel high-performance liquid chromatographic method using solid-phase on-line elution for determination of metolazone in plasma and whole blood. (1994) (23)
- Effect of ketoconazole on the pharmacokinetics and safety of telithromycin and clarithromycin in older subjects with renal impairment. (2005) (22)
- The prevalence of salt sensitivity in an African-American adolescent population. (1999) (22)
- Hydrochlorothiazide vs chlorthalidone, indapamide, and potassium‐sparing/hydrochlorothiazide diuretics for reducing left ventricular hypertrophy: A systematic review and meta‐analysis (2018) (22)
- Calcium-channel blockers and end-stage renal disease: pharmacokinetic and pharmacodynamic considerations (2003) (22)
- Central sympathetic blockade ameliorates brain death-induced cardiotoxicity and associated changes in myocardial gene expression. (2002) (21)
- Abstract 2751: An Implantable Carotid Sinus Baroreflex Activating System for Drug-Resistant Hypertension: Interim Chronic Efficacy Results from the Multi-Center Rheos Feasibility Trial (2006) (20)
- Chlorthalidone – a renaissance in use? (2009) (20)
- Pharmacotherapy in congestive heart failure: aldosterone receptor antagonism: interface with hyperkalemia in heart failure. (2004) (20)
- High Fat High Cholesterol Diet (Western Diet) Aggravates Atherosclerosis, Hyperglycemia and Renal Failure in Nephrectomized LDL Receptor Knockout Mice: Role of Intestine Derived Lipopolysaccharide (2015) (20)
- Acute phosphate nephropathy following colonoscopy preparation. (2007) (20)
- Subcutaneous Furosemide in Heart Failure (2018) (20)
- Sodium, Potassium, the Sympathetic Nervous System, and the Renin-Angiotensin System: Impact on the Circadian Variability in Blood Pressure (2000) (20)
- ACE Inhibitors and Anemia in Congestive Heart Failure (2000) (19)
- The Heart Outcomes Prevention Evaluation study: angiotensin-converting enzyme inhibitors: are their benefits a class effect or do individual agents differ? (2001) (19)
- Hydrochlorothiazide and alternative diuretics versus renin–angiotensin system inhibitors for the regression of left ventricular hypertrophy: a head-to-head meta-analysis (2017) (19)
- Baroreflex activation for the treatment of hypertension: principles and practice (2006) (19)
- Chlorthalidone versus hydrochlorothiazide as the preferred diuretic: is there a verdict yet? (2011) (18)
- Review: The pharmacokinetics and pharmacodynamics of angiotensin-receptor blockers in end-stage renal disease (2002) (18)
- Effect of Pancreatico-Biliary Secretions and GI Transit Time on the Absorption and Pharmacokinetic Profile of Ranitidine in Humans (1998) (18)
- Violence Exposure and Ambulatory Blood Pressure in African-American Adolescents (1998) (18)
- The risks and benefits of aldosterone antagonists (2005) (18)
- The effects of dichloromethylene diphosphonate on hypercalcemia and other parameters of the humoral hypercalcemia of malignancy in the rat leydig cell tumor (1983) (18)
- The risks and benefits of therapy with aldosterone receptor antagonist therapy. (2007) (17)
- Liquid chromatography method for determination of bivalirudin in human plasma and urine using automated ortho-phthalaldehyde derivatization and fluorescence detection. (2004) (17)
- The implications of renal impairment among patients undergoing percutaneous coronary intervention. (2002) (17)
- Gender and its effect in cardiovascular pharmacotherapeutics: recent considerations. (2005) (17)
- Dosage considerations with perindopril for systemic hypertension. (2001) (17)
- Effect of omega-3-acid ethyl esters on the steady-state plasma pharmacokinetics of rosuvastatin in healthy adults. (2008) (16)
- Renal handling of angiotensin receptor blockers: Clinical relevance (2003) (16)
- Therapeutic Considerations in the African‐American Patient With Hypertension: Considerations With Calcium Channel Blocker Therapy (2005) (16)
- Nifedipine plus candesartan combination increases blood pressure control regardless of race and improves the side effect profile: DISTINCT randomized trial results (2014) (16)
- Hyponatremia in spinal cord injury. (1990) (15)
- Hyperkalemia risk in chronic kidney disease: deterrent to the use of aldosterone receptor antagonism or not. (2009) (15)
- The Antihypertensive Efficacy and Safety of a Chronotherapeutic Formulation of Propranolol in Patients With Hypertension (2004) (15)
- Impact of low-dose B-type natriuretic peptide infusion on urine output after total artificial heart implantation. (2012) (15)
- Hypertension Primer 4/e (The Essentials of High Blood Pressure: Basic Science, Population Science, and Clinical Management From the Council on High Blood Pressure Research, American Heart Association) (2007) (15)
- Severe hypophosphatemia after head injury. (1985) (15)
- Not Just Chlorthalidone: Evidence-Based, Single Tablet, Diuretic Alternatives to Hydrochlorothiazide for Hypertension (2015) (14)
- Pathologic basis and treatment considerations in chronic kidney disease-related hypertension. (2005) (14)
- A Modern Perspective on β‐Blocker Use in Hypertension: Clinical Trials and Their Influence on Clinical Practice (2007) (14)
- Impact of antihypertensive therapy on the rate-pressure product : the role of chronotherapeutics (1999) (14)
- Public-use blood pressure measurement: the kiosk quandary. (2014) (14)
- Long-term safety and tolerability of the oral direct renin inhibitor aliskiren with optional add-on hydrochlorothiazide in patients with hypertension: a randomized, open-label, parallel-group, multicentre, dose-escalation study with an extension phase. (2011) (13)
- A rapid and simple chemiluminescence method for screening levels of inosine and hypoxanthine in non-traumatic chest pain patients. (2011) (13)
- High-performance liquid chromatography (HPLC) determination of inosine, a potential biomarker for initial cardiac ischaemia, using isolated mouse hearts (2006) (13)
- Racial differences in the renal response to blood pressure lowering during chronic angiotensin-converting enzyme inhibition: a prospective double-blind randomized comparison of fosinopril and lisinopril in older hypertensive patients with chronic renal insufficiency. (1997) (13)
- Quantitation of metolazone in urine by high-performance liquid chromatography with fluorescence detection. (1990) (13)
- Use of diuretics in the treatment of heart failure in the elderly. (2007) (13)
- Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 6: Hypertension: A Scientific Statement from the American Heart Association and the American College of Cardiology. (2015) (13)
- Pharmacokinetic Comparison of Flurbiprofen in End‐Stage Renal Disease Subjects and Subjects with Normal Renal Function (1991) (13)
- Furosemide pharmacokinetics and pharmacodynamics in renal transplantation (1988) (13)
- Cyclosporine's effect on functional reserve in the renal allograft. (1991) (12)
- Combination ACE Inhibitor and Angiotensin Receptor Blocker Therapy—Future Considerations (2007) (12)
- The Evolution of Renin-Angiotensin Blockade: Angiotensin-Converting Enzyme Inhibitors as the Starting Point (2010) (12)
- ACE inhibitor intolerance and lessons learned from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) trials. (2004) (12)
- Calcium channel blockers and the kidney. (2004) (12)
- Cardiovascular Disease in African Americans (2004) (12)
- Cerebrospinal fluid aluminum levels following deferoxamine. (1990) (12)
- Antiarrhythmic Medications (1990) (12)
- Case Report: Severe Hyponatremia in Spinal Cord Injury (1989) (12)
- Effects of combining azilsartan medoxomil with amlodipine in patients with stage 2 hypertension (2014) (12)
- Hypercalcemic hypertension in hemodialysis. (1984) (12)
- Doxazosin and congestive heart failure. (2002) (12)
- Are There Pleiotropic Effects of Antihypertensive Medications or Is It All About the Blood Pressure in the Patient With Diabetes and Hypertension? (2011) (11)
- Severe hyponatremia in spinal cord injury. (1989) (11)
- Angiotensin II and Thirst: Therapeutic Considerations (2001) (11)
- Pharmacologic considerations in the positioning of β-blockers in antihypertensive therapy (2008) (11)
- Single-Center Evaluation of the Single-Dose Pharmacokinetics of the Angiotensin II Receptor Antagonist Azilsartan Medoxomil in Renal Impairment (2013) (11)
- Edema mechanisms in the patient with heart failure and treatment options. (2008) (10)
- The Valsartan Antihypertensive Long-Term Use Evaluation trial: a study in contrasts. (2006) (10)
- The hypercalcemic rat leydig cell tumor—A model of the humoral hypercalcemia of malignancy (1983) (10)
- Fosinopril pharmacokinetics and pharmacodynamics in chronic ambulatory peritoneal dialysis patients (2004) (10)
- Chapter 18 – Diuretic Therapy in Cardiovascular Disease (2007) (10)
- COMPARISON OF ANTIHYPERTENSIVE EFFICACY OF THE NEW ANGIOTENSIN RECEPTOR BLOCKER AZILSARTAN MEDOXOMIL WITH RAMIPRIL: PP.16.112 (2010) (10)
- Hypertension Treatment Guidelines (2004) (10)
- β‐Blockers in Hypertension: A Reassessment of the Benefit of Combined α‐/β‐Blockade (2007) (10)
- Evaluation of the Renal Protective Effect of Misoprostol in Elderly, Osteoarthritic Patients at Risk for Nonsteroidal Anti‐inflammatory Drug‐Induced Renal Dysfunction (1993) (10)
- The pharmacokinetics and pharmacodynamics of fosinopril in haemodialysis patients (2004) (10)
- Aldosterone and volume management in hypertensive heart disease. (2014) (10)
- Are current strategies for treating hypertension effective? (2003) (10)
- The Pharmacokinetics and Pharmacodynamics of Losartan in Continuous Ambulatory Peritoneal Dialysis (2000) (10)
- Drospirenone: an antihypertensive in waiting. (2006) (10)
- Cefmenoxime pharmacokinetics in patients with renal insufficiency (1984) (9)
- Does the benefit from treating to lower blood pressure targets vary with age? A systematic review and meta-analysis. (2019) (9)
- Long-Term Safety and Tolerability of the Oral Direct Renin Inhibitor Aliskiren with Optional Add-On Hydrochlorothiazide in Patients with Hypertension (2012) (9)
- Direct Vasodilators and their Role in Hypertension Management: Minoxidil (2001) (9)
- The Renal Profile of Eprosartan (1999) (9)
- Old antihypertensive agents-diuretics and β-Blockers: Do we know how and in whom they lower blood pressure? (1999) (9)
- Pharmacologic Issues in treating hypertension in CKD. (2011) (9)
- Case Report: Pseudoephedrine Accumulation in Renal Failure (1989) (9)
- Treatment with enalapril fails to prevent impaired cardiopulmonary baroreflex control in dogs with left ventricular dysfunction. (1995) (9)
- Use of Enoxaparin in Patients with Chronic Kidney Disease (2007) (9)
- Valsartan/hydrochlorothiazide. Commentaries (1999) (9)
- Ranitidine pharmacokinetics in continuous ambulatory peritoneal dialysis (2006) (9)
- Device-guided breathing and hypertension: a yet to be determined positioning. (2011) (9)
- Fixed‐Dose Combination Therapy—Is It Time for This Approach to Hypertension and Dyslipidemia Management? (2004) (9)
- Pharmacologic and Therapeutic Considerations in Hypertension Therapy With Calcium Channel Blockers: Focus on Verapamil (2007) (9)
- The Role of the Renin-Angiotensin System in Cholesterol and Puromycin Mediated Renal Injury (2002) (9)
- Evaluation of the angiotensin II receptor blocker azilsartan medoxomil in African‐American patients with hypertension (2017) (8)
- ANTIHYPERTENSIVE EFFICACY OF THE NOVEL ANGIOTENSIN RECEPTOR BLOCKER AZILSARTAN MEDOXOMIL IN COMBINATION WITH AMLODIPINE: PP.16.99 (2010) (8)
- A direct injection method for determing furosemide and metolazone in urine high performance liquid chromatography and fluorescence detection (1991) (8)
- Effects of salicylic acid on post-ischaemic ventricular function and purine efflux in isolated mouse hearts (2007) (8)
- Pharmacokinetics and protein binding of methocarbamol in renal insufficiency and normals (2004) (8)
- Simple method for simultaneous determination of halothane, enflurane, and isoflurane in Krebs solution using capillary gas chromatography. (1997) (8)
- Endothelial cell function : new considerations (2000) (8)
- Pamidronate-induced kidney injury in a patient with metastatic breast cancer. (2009) (8)
- Atrial natriuretic factor in spinal cord injury. (1993) (8)
- A Guide to the Management of Blood Pressure in the Diabetic Hypertensive Patient (2009) (8)
- Angiotensin‐Converting Enzyme Inhibitor Use in the Year 2005 (2005) (8)
- COX-2 Inhibition: A Cautionary Note in Congestive Heart Failure (2000) (7)
- Ophthalmically Administered β Blockers and Their Cardiopulmonary Effects (2001) (7)
- The Losartan Intervention for Endpoint Reduction (LIFE) Trial—Have Angiotensin‐Receptor Blockers Come of Age? (2002) (7)
- The influence of potassium on ambulatory blood pressure non-dipping status in salt-sensitive versus salt-resistant black adolescents (1998) (7)
- Pharmacodynamics(PD) and kinetics (PK) of bivalirudin (BIV) in renal failure (RF) and hemodialysis (HD) (1999) (7)
- Angiotensin-converting enzyme inhibitor-related angioedema: recognition and treatment. (2007) (7)
- Optimizing hypertension and vascular health: focus on ethnicity. (2004) (7)
- Angiotensin-converting enzyme inhibition-emerging pulmonary issues relating to cough. (2006) (7)
- "Translational" medicine: transforming SPRINT findings into clinical practice. (2016) (6)
- Nesiritide Appears To Inhibit the Rise in Plasma Aldosterone Associated with Furosemide Diuresis (2006) (6)
- Aldosterone receptor blockade: a therapy resurrected. (2003) (6)
- Antihypertensive efficacy of night-time graded-release diltiazem versus morning amlodipine in African Americans. (2004) (6)
- Hypertension optimal treatment (HOT) study : Successes and failures (1999) (6)
- Phase IIa Study of the NPR-A Agonist, PL-3994, in Healthy Adult Volunteers with Controlled Hypertension (2009) (6)
- Pharmacotherapy in congestive heart failure: Cardiopulmonary effects of ophthalmically administered beta-blockers. (1999) (6)
- Spironolactone use in resistant hypertension (2007) (6)
- Use of Diuretics in the Treatment of Heart Failure in Older Adults. (2017) (6)
- Diuretics in congestive heart failure. (1989) (6)
- Review: The practical aspects of combination therapy with angiotensin receptor blockers and angiotensin-converting enzyme inhibitors (2002) (6)
- P-170: Eplerenone and serum potassium change-relationship to renal function (2003) (6)
- Ranitidine bioavailability and disposition kinetics in patients undergoing chronic hemodialysis. (1989) (6)
- Clinical Pharmacology of the Angiotensin Receptor Antagonists (2001) (6)
- Desmopressin : safety considerations in patients with chronic renal disease. (2006) (5)
- Angiotensin-receptor blockers: Another victory (2002) (5)
- Review: Rationale for combination therapy in the treatment of hypertension (2002) (5)
- Once-daily effects of the angiotensin receptor blocker, eprosartan on 24-hour blood pressure in patients with systemic hypertension (1999) (5)
- ACHIEVEMENT OF BLOOD PRESSURE GOAL IN PATIENTS WITH RESISTANT HYPERTENSION TREATED WITH BAROREFLEX ACTIVATION THERAPY®: PP.16.107 (2010) (5)
- Pharmacotherapy in congestive heart failure: angiotensin II and thirst: therapeutic considerations. (2001) (5)
- A randomized titrate-to-target study comparing fixed-dose combinations of azilsartan medoxomil and chlorthalidone with olmesartan and hydrochlorothiazide in stage-2 systolic hypertension (2018) (5)
- Total VolumeCulture Technique fortheIsolation ofMicroorganisms fromContinuous Ambulatory Peritoneal Dialysis Patients withPeritonitis (1985) (5)
- Taking the pressure off type 2 diabetes mellitus: implementing hypertension guidelines. (2007) (5)
- Fixed-dose combination antihypertensive drugs : Principles and practice (1997) (5)
- The importance of the sympathetic nervous system and systolic hypertension in patients with hypertension: benefits in treating patients with increased cardiovascular risk. (2000) (5)
- Endothelin receptor antagonism: what does the future hold? (2008) (5)
- Do pleiotropic effects of antihypertensive medications exist or is it all about the blood pressure? (2008) (5)
- Diuretics should continue to be one of the preferred initial therapies in the management of hypertension: the argument against. (2005) (4)
- Design of a novel controlled-release formulation of carvedilol: pharmacology and clinical aspects. Introduction. (2006) (4)
- RESULTS OF A NOVEL ANGIOTENSIN RECEPTOR BLOCKER, AZILSARTAN MEDOXOMIL, IN PATIENTS WITH PRIMARY HYPERTENSION: 9A.01 (2010) (4)
- Current Concepts of Pharmacotherapy in Hypertension - Fixed Dose Combination Antihypertensive Therapy: Is This the Future? (2000) (4)
- Effect of omega-3-acid ethyl esters on the steady-state plasma pharmacokinetics of rosuvastatin in healthy adults (2008) (4)
- BAROREFLEX HYPERTENSION THERAPY IMPROVES CARDIAC STRUCTURE AND FUNCTION IN RESISTANT HYPERTENSION: RESULTS FROM THE PIVOTAL TRIAL OF THE RHEOS SYSTEM (2011) (4)
- THE NEW ANGIOTENSIN RECEPTOR BLOCKER AZILSARTAN MEDOXOMIL HAS SIGNIFICANTLY GREATER 24-HOUR BLOOD PRESSURE LOWERING EFFICACY TO BOTH OLMESARTAN AND VALSARTAN: 9D.05 (2010) (4)
- The practical aspects of combination therapy with angiotensin receptor blockers and angiotensin-converting enzyme inhibitors. (2002) (4)
- Beyond conventional considerations: newer devices used in blood pressure measurement and management. (2011) (4)
- Lessons learned from prematurely terminated clinical trials (2001) (4)
- JNC 7: has the definition of hypertension changed? (2003) (4)
- The Renin-Angiotensin Axis Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers (2011) (4)
- Renal Sympathetic Denervation for the Treatment of Systemic Hypertension (2012) (4)
- THE EFFECTS OF RENAL PARENCHYMAL PRESSURE ON RENAL FUNCTION (1999) (4)
- Peritoneal dialysis in spinal cord injury. (1986) (4)
- 558 AZILSARTAN MEDOXOMIL VS OLMESARTAN AND VALSARTAN: EFFECTS ON AMBULATORY AND CLINIC BP IN HYPERTENSIVE BLACK PATIENTS (2012) (4)
- Management of hypertension in the outpatient setting. (2008) (4)
- Pharmacokinetics of procainamide in continuous ambulatory peritoneal dialysis. (1988) (4)
- Cardiopulmonary baroreflex control of renal sympathetic nerve activity is impaired in dogs with left ventricular dysfunction. (2019) (4)
- Pseudoephedrine accumulation in renal failure. (1989) (4)
- Current concepts of pharmacotherapy in hypertension--ophthalmically administered beta blockers and their cardiopulmonary effects. (2001) (4)
- The pharmacology of agents that interfere with renin-angiotensin system activity (2006) (4)
- Chlorella Supplementation for Controlling Hypertension: A Clinical Evaluation (2002) (4)
- Current Concepts of Pharmacotherapy in Hypertension - Alpha-Adrenergic Blocking Drugs: Evolving Role in Clinical Medicine. (2000) (4)
- The pharmacokinetics and pharmacodynamics of angiotensin-receptor blockers in end-stage renal disease. (2002) (4)
- Sodium, Potassium, the Sympathetic Nervous System, and the Renin—Angiotensin System (2001) (4)
- Pharmacotherapy in congestive heart failure. Prematurely terminated clinical trials and their application to cardiovascular medicine. (2001) (4)
- Assessment of the Role of ACE Inhibitors in the Elderly (2005) (3)
- Hypertension treatment: how important is consistency of effect? (2007) (3)
- EUROPA: Has Anything New Been Learned With Angiotensin‐Converting Enzyme Inhibitors? (2004) (3)
- Steady-state plasma levels and pharmacokinetics of guanfacine in patients with renal insufficiency. (1989) (3)
- Edema Mechanisms in the Heart Failure Patient and Treatment Options (2012) (3)
- Fosinopril: Emerging Considerations and Implications for Angiotensin‐Converting Enzyme Inhibitor Therapy (1998) (3)
- E029: Losartan (LOS) and Uric Acid (UA) in chronic renal failure and End-Stage Renal Disease (ESRD) (1998) (3)
- A guide to the management of blood pressure in the diabetic hypertensive patient. (2009) (3)
- Strategies to improve the cardiovascular risk profile of thiazide-type diuretics as used in the management of hypertension (2007) (3)
- The Renin Report. (2006) (3)
- ALLHAT: is the final answer in? (2003) (3)
- Vasopeptidase Inhibition and its Role in Congestive Heart Failure (2000) (2)
- The effect of nonsteroidal agents (NSAIDs) on the pharmacokinetics and pharmacodynamics of metolazone. (1994) (2)
- Review of eprosartan: a new angiotensin II receptor antagonist. Summary. (1999) (2)
- Current Concepts of Pharmacotherapy in Hypertension - ACE Inhibitors: Current Considerations in Their Use. (1999) (2)
- Pharmacokinetics of torsemide in chronic renal insufficiency (1991) (2)
- Prostaglandin E2 excretion in spinal cord injury patients. (1984) (2)
- Nondrug Interventions for the Treatment of Hypertension: Varying Effect (2012) (2)
- Medullary sponge kidney and staghorn calculi. (1990) (2)
- Calcium Channel Blockers: Monotherapy and Dual Therapy Considerations in the Treatment of Hypertension (2007) (2)
- Newer Antihypertensive Agents (2003) (2)
- Magnesium , Potassium , and Calcium as Cardiovascular Disease Therapies (2011) (2)
- Renovascular disease in blacks: prevalence and result of operative management. Consortium of Southeastern Hypertension Control. (1998) (2)
- Pharmacotherapy in congestive heart failure: Effect of the insertion/deletion polymorphism of the ACE gene on response to ACE inhibitors in patients with heart failure. (1999) (2)
- Practical Guidelines for Drug Therapy in Dialysis (1995) (2)
- Do pleiotropic effects of antihypertensive medications exist or is it all about the blood pressure? (2007) (2)
- Pharmacotherapy in congestive heart failure: Hyperkalemia in congestive heart failure. (2001) (2)
- Novel combinations in the treatment of hypertension. (2005) (2)
- Diuretics as Monotherapy or as Part of Combination Therapy for Hypertension: An Update (2008) (2)
- Patient Characteristics Associated With Resistant Hypertension Older age High baseline blood pressure Obesity Excessive dietary salt ingestion Chronic kidney disease Diabetes Left ventricular hypertrophy Black race Female sex (2008) (2)
- Pharmacotherapy in congestive heart failure: Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in congestive heart failure: do they differ in their renal effects in man? (2001) (2)
- NEW ANGIOTENSIN II RECEPTOR BLOCKER AZILSARTAN MEDOXOMIL: COMPARISON TO VALSARTAN: PP.16.88 (2010) (2)
- New Considerations Relating to Class Effect With Angiotensin‐Converting Enzyme Inhibitors‐The PEACE Study (2005) (2)
- Hypertension and End‐Organ Disease in African Americans: Case Presentations (2004) (2)
- What is the Role of Aldosterone Excess in Resistant Hypertension and How Should It Be Investigated and Treated? (2011) (2)
- Calcium Channel Blockers: A More Expansive Treatment Role (2005) (2)
- Use of diuretics in the treatment of heart failure in the elderly. (2007) (2)
- ACE inhibitors and stroke: new considerations. (2002) (2)
- Renal function, diuretic action, and heart failure: a therapeutic conundrum. (2007) (2)
- Metolazone pharmacokinetics and pharmacodynamics in renal transplantation. (1991) (2)
- Renin–Angiotensin Blockade: Therapeutic Agents (2009) (2)
- Violence exposure, catecholamine excretion, and blood pressure non-dipping status in African-American adolescents (2001) (2)
- P-409: Organic anion transport and the renal handling of losartan (2002) (2)
- Effect of dietary sodium (Na+) on urinary 6-beta-hydroxycortisol excretion in salt-sensitive (SS) and salt-resistant (SR) adolescent African-Americans. (1996) (2)
- Calcium Channel Blockers (2011) (2)
- The editor's roundtable: prehypertension. (2009) (2)
- Geriatric nephrology and urology (1985) (2)
- BiDil (isosorbide dinitrate and hydralazine hydrochloride). (2006) (1)
- Chapter 65 – Angiotensin-Converting Enzyme Inhibitors (2005) (1)
- Pyomyositis in spinal cord injury patients (1989) (1)
- Dual Inhibitors: RAAS Blockers/Combination Therapies: What Do All These Trials Mean? (2015) (1)
- Cefmenoxime kinetics during continuous ambulatory peritoneal dialysis (2004) (1)
- More salt is better: a novel management approach to acute decompensated heart failure. (2014) (1)
- Aha Scientific Statement Secondary Prevention after Coronary Artery Bypass Graft Surgery a Scientific Statement from the American Heart Association on Behalf of the American Heart Association Council on Cardiovascular Surgery and Anesthesia (1)
- Obstructive sleep apnea, hypertension, and wakefulness-promoting agents (2007) (1)
- Baroreflex Activation in Drug-resistant Hypertension (2009) (1)
- Centrally Acting Antihypertensive Agents in the Treatment of Hypertension (2015) (1)
- Angiotensin Receptor Blockers and the Risk of Malignancy (2010) (1)
- Chapter 31 – Pharmacologic Treatment of Hypertension (2007) (1)
- Is there HOPE for ALLHAT: similarities and differences (2003) (1)
- Angiotensin receptor blockers and drug–drug interactions (2005) (1)
- A Review of Antihypertensive Drugs and Choosing the Right Antihypertensive for Recurrent Stroke Prevention (2016) (1)
- A015: Extreme dipping — a definitional dilemma. (1999) (1)
- Effect of Ketoconazole on The Pharmacokinetics and Safety of Telithromycin and Clarithromycin in Elderly Subjects With Diminished Renal Function (2003) (1)
- Current Concepts of Pharmacotherapy in Hypertension: Clinical Implications of the Dose Response Relationship of Antihypertensive Medication in the Treatment of Hypertension. (1999) (1)
- Current Concepts of Pharmacotherapy in Hypertension - Diuretics: Where Have We Been and Where Are We Going. (1999) (1)
- Drug absorption in congestive heart failure: impact on management. (1999) (1)
- P-567: Baroreflex hypertension therapy for resistant hypertension (2005) (1)
- Proceedings from the Society of Interventional Radiology Foundation Research Consensus Panel on Renal Sympathetic Denervation. (2014) (1)
- Chapter 53 – Hypertension in Patients on Renal Replacement Therapy (2005) (1)
- Drug absorption in congestive heart failure: impact on management. (1999) (1)
- Considerations in Drug Handling in Renal Disease (2007) (1)
- Angiotensin‐Converting Enzyme Inhibitors' Side Effects—Physiologic and Non‐Physiologic Considerations (2005) (1)
- Clinical Trials Report (2004) (1)
- for High Blood Pressure Research From the American Heart Association Professional Education Committee of the Council Resistant Hypertension: Diagnosis, Evaluation, and Treatment : A Scientific Statement (2013) (1)
- E030: The antihypertensive and neurohumoral effects of Losartan (LOS) in End-Stage Renal Disease (ESRD) Peritoneal Dialysis (PD) patients (1998) (1)
- Antihypertensive regimens with ACE inhibitors slow the progression of non-diabetic renal disease more than regimens without ACE-inhibitors (2002) (1)
- Can focused US with a diagnostic US contrast agent favorably affect renal function? (2009) (1)
- Chapter 83 – Centrally Acting Agents (2007) (1)
- Over‐the‐Counter Statin Therapy—Pros and Cons (2005) (1)
- Pharmacotherapy in congestive heart failure: Vasopeptidase inhibition and its role in congestive heart failure. (2000) (1)
- How Important Is Consistency of Effect? (2007) (0)
- THE USE OF COMBINATION THERAPY BENEFITS ALL HYPERTENSIVE PATIENTS (POOR AND EXCELLENT RESPONDERS TO MONOTHERAPY) WHOSE BP WAS UNCONTROLLED: 9A.07 (2010) (0)
- Angiotensin-receptor Blocker Therapy – Chronic Kidney Disease and Diabetes (2006) (0)
- On the waterfront. (2011) (0)
- H2 Success of an inner-city, free-standing, hypertension specialty clinic for indigent patients (1997) (0)
- Editorial ''Translational'' medicine: transforming SPRINT findings into clinical practice (2016) (0)
- Hypertension and Its Treatment in Concomitant Conditions (2001) (0)
- RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY INVESTIGATING CHANGES IN NOCTURNAL BLOOD PRESSURE ELEVATIONS ASSOCIATED WITH PERIODIC LEG MOVEMENTS FOLLOWING TREATMENT WITH ROTIGOTINE IN PATIENTS WITH RESTLESS LEGS SYNDROME (WILLIS-EKBOM DISEASE) (2014) (0)
- I014: Dopaminergic control of aldosterone release is not determined by race or salt sensitivity (2000) (0)
- Hypertension and Its Treatment in Concomitant Conditions: Degenerative Joint Disease, Depression, Alzheimer Disease, and Parkinson Disease (2000) (0)
- Placebo-Controlled Rheos Pivotal Trial Resistant Hypertension: Results From the Double-Blind, Randomized, Baroreflex Activation Therapy Lowers Blood Pressure in Patients With (2011) (0)
- Synthesizing the Current Use of Generics in Cardiovascular Disease (2020) (0)
- Valsartan/Hydrochlorothiazide (2012) (0)
- Pharmacological and Pharmacodynamic Alterations in the Elderly (2005) (0)
- 243 HDL MEDIATED CHOLESTEROL EFFLUX FROM MESANGIAL CELLS: THE ROLE OF MAP KINASE. (2004) (0)
- Case of Refractory Hypertension Controlled After Aortic and Mitral Valve Replacement and Coronary Artery Bypass Grafting. (2018) (0)
- Saralasin Acetate Test in Renal Transplant Hypertension: Report of 17 Cases and a Review of the Literature (1984) (0)
- Reflections on Diabetes, Clinical Trials, and Cardiovascular Morbidity and Mortality (2000) (0)
- Diuretics for the Treatment of Hypertension (2015) (0)
- Board of Directors and Membership Benefits (2008) (0)
- Role of Afferent and Efferent Renal Sympathetic Nerves in HTN (2014) (0)
- for Chapter 11 Diuretic Therapy in Cardiovascular Disease (2011) (0)
- Angiotensin-receptor blockers for prehypertension. (2006) (0)
- Clinical trials report (2006) (0)
- DOES GLOMERULAR FILTRATION RATE AFFECT THE BP RESPONSE TO ANGIOTENSIN RECEPTOR BLOCKER (ARB) MONOTHERAPY OR TO COMBINED ARB + HYDROCHLOROTHIAZIDE (HCTZ) THERAPY?: PP.9.366 (2010) (0)
- Board of Directors and Membership Benefits (2012) (0)
- Differential Diagnosis of Medullary Sponge Kidney (1984) (0)
- Long-term safety of fixed-dose combinations: azilsartan medoxomil/chlorthalidone (AZL-M/CLD) vs olmesartan medoxomil/hydrochlorothiazide (OLM/HCTZ) in hypertensive subjects with stage 3 chronic kidney disease (2014) (0)
- C008: Cholesterol (CHOL) exacerbates hypertension in puromycin (P) induced focal glomerulosclerosis (FGS) (1998) (0)
- Dose-response relationships of potassium sparing diuretics to systolic blood pressure and serum potassium from randomized trials (2015) (0)
- The Role of Irbesartan in Hypertension and Diabetic Kidney Disease (1999) (0)
- 555 Nesiritide Improves Urine Output after Ventriculectomy and Placement of the Total Artificial Heart (2012) (0)
- Newer Antihypertensive Agents: Angiotensin-Receptor Antagonists and Vasopeptidase Inhibitors (2001) (0)
- The New Hypertension Guidelines: Hits and Misses (2021) (0)
- Efficacy and Safety of Atrasentan in Patients With Cardiovascular Risk and Early Atherosclerosis. Commentary (2008) (0)
- 9 – Edema and the Clinical Use of Diuretics (2014) (0)
- Chlorthalidone-arenaissance inuse? (2009) (0)
- Meta-Analyses of ARBs to Elucidate Link to Cancer, MI, and Dementia (2013) (0)
- D016: Methods for determining salt-sensitivity in adolescent outpatient populations (1998) (0)
- P-336: The role of gender, environmental and psychosocial factors in non-dipping status for blood pressure (2002) (0)
- Consensus Panel on Renal Sympathetic Denervation (2014) (0)
- EUROPA: Has Anything New Been Learned With Angiotensin‐Converting Enzyme Inhibitors? (2005) (0)
- The Use of Portacath Placement for Saline Infusions for the Treatment of Postural Orthostatic Tachycardia Syndrome (2015) (0)
- Clinical Trials Report (2003) (0)
- Gender differences in non-dipping status and catecholamine responses in black adolescents (2000) (0)
- AZILSARTAN MEDOXOMIL/CHLORTHALIDONE FIXED-DOSE COMBINATION LOWERS BP MORE THAN OLMESARTAN/HYDROCHLOROTHIAZIDE FIXED-DOSE COMBINATION IN STAGE 2 SYSTOLIC HYPERTENSION: LB3.4 (2011) (0)
- Pharmacotherapy in congestive heart failure: reflections on diabetes, clinical trials, and cardiovascular morbidity and mortality. (2000) (0)
- F5 The influence of potassium intake on dipper vs. non-dipper blood pressure status in adolescents (1997) (0)
- Severe Hypophosphatemia(h) in Head Trauma (ht) Patients (1984) (0)
- FIXED-DOSE COMBINATION OF AZILSARTAN MEDOXOMIL/CHLORTHALIDONE PROVIDES SUPERIOR BP REDUCTION TO MONOTHERAPIES IN STAGE 2 HYPERTENSION: PP.14.382 (2011) (0)
- PHARMACOKINETIC AND PHARMACODYNAMIC RESPONSE TO ORAL AND SUBCUTANEOUS FUROSEMIDE ADMINISTRATION: FIRST EXPERIENCES WITH A NOVEL BUFFERED FUROSEMIDE FORMULATION IN PATIENTS WITH CHRONIC HEART FAILURE (2016) (0)
- Angiogenesis Inhibitors and Hypertension (2007) (0)
- F003: Kaliuresis with furosemide is determined by race but not salt sensitivity (2000) (0)
- Chapter 20 – Angiotensin-Converting Enzyme Inhibitors (2007) (0)
- Electrolyte Disturbances and Cardiopulmonary Resuscitation (2005) (0)
- Comprar Clinical challenges in hypertension II | Toth, P.P. | 9781846920691 | Clinical Pub. (2010) (0)
- Narcotic usage in renal failure. (1988) (0)
- Summary (1999) (0)
- Do Thiazide Diuretics Cause Diabetes? If So, Is It of Clinical Significance? (2016) (0)
- Urinary potassium excretion: can it predict the onset of hypertension? (2014) (0)
- Roundtable Discussion: Electrolytes in Cardiovascular Disease and Hypertension (2003) (0)
- EFFICACY AND SAFETY OF AZILSARTAN MEDOXOMIL/CHLORTHALIDONE WITH OLMESARTAN/HYDROCHLOROTHIAZIDE COMBINATIONS IN STAGE 2 SYSTOLIC HYPERTENSION: 4A.09 (2011) (0)
- Cardiopulmonary baroreflexes modulate norepinephrine levels in dogs with left ventricular dysfunction (1999) (0)
- P-252: Pharmacokinetics of propranolol following single and multiple-dosing with Inderal-LA or a chrontherapeutic form of propranolol (2003) (0)
- P-559: Socioeconomic status, social support and nighttime BP in African-American adolescent males and females (2003) (0)
- All Patients with Uncontrolled Blood Pressure on Valsartan Monotherapy Benefit from Switch to Combination Therapy (2010) (0)
- Clinical trials report. Consequences of new-onset diabetes during the treatment of hypertension. (2004) (0)
- Cerebrovascular Disease: Does brain nitric oxide generation influence tissue oxygenation after severe human subarachnoid hemorrhage? (2002) (0)
- Effects of short IV infusions of DT‐009, a novel adenosine (A1−) receptor agonist, on renal function in healthy subjects (2005) (0)
- Drug combinations in the treatment of hypertension: never-ending novelty. (2010) (0)
- Orbofiban single dose pharmacokinetics (PK) and pharmacodynamics (PD) in renal failure (RF) and hemodialysis (HD) (1999) (0)
- B17 Preexisting hypertension (H) augments puromycin (P) induced nephrosis. The role of angiotensin II (1997) (0)
- Renin–Angiotensin Blockade (2018) (0)
- HDL MEDIATED CHOLESTEROL EFFLUX FROM MESANGIAL CELLS: THE ROLE OF MAP KINASE.: 243 (2004) (0)
- Novel Therapeutic Concepts Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction : integrating evidence into clinical practice (2012) (0)
- Ultrafiltration for acute decompensated heart failure: has its time come? (2006) (0)
- D24 - A chronotherapeutic approach to antihypertensive therapy: Nocturnal dosing of a novel delivery system of verapamil (1995) (0)
- The Role of Older Pharmacological Therapies in Cardiovascular Disease (2020) (0)
- Clinical trials report. White-coat hypertension and stroke incidence. (2005) (0)
- Cefmenoxime Pharmacokinetics inPatients withRenalInsufficiency (1984) (0)
- Clinical Trials Report (2005) (0)
- Sleep: yet to be mapped waters for blood pressure. (2011) (0)
- Abstract 075: Does the Benefit From Treating to Blood Pressure Targets Vary With Age? (2018) (0)
- Mechanisms of hypertension — Opportunities to individualize on the basis of pathophysiology and pharmacokinetics (1998) (0)
- Lipids and Guidelines -- "Let Me Be Simple-Minded Doctor!!" LDL-C Less Than 70 mg/dL and Pay Attention to HDL (2020) (0)
- OR-74: Once nightly dosing and steady state pharmacokinetics of circadian extended-release propranolol hydrochloride in patients with essential hypertension (2003) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Domenic A. Sica?
Domenic A. Sica is affiliated with the following schools:
